Literature DB >> 9182883

Restricted expression of Fc gammaRIII (CD16) in synovium and dermis: implications for tissue targeting in rheumatoid arthritis (RA).

J C Edwards1, S Blades, G Cambridge.   

Abstract

Interactions between immune complexes and immunoglobulin Fc receptors may contribute to inflammation in RA. Previous studies suggested that Fc gammaRIII (CD16) may be preferentially expressed in diseased synovial intima. The distribution of immunoreactive Fc gammaRIII was examined in normal fetal limb tissues, and both normal and selected abnormal samples of adult synovium and skin. In fetal limbs at 10-14 weeks gestation Fc gammaRIII was restricted to synovial intima. In normal adult synovium Fc gammaRIII was restricted to intimal cells. In inflamed synovia differential expression of Fc gammaRIII in the intima was less consistent. In both fetal and adult synovium Fc gammaRIII was largely restricted to cells expressing CD45 (leucocyte common antigen). Staining for Fc gammaRIII was, however, occasionally associated with CD45 intimal cells in fetal synovium. In both fetal and adult tissues cell membrane Fc gammaRIII was frequently closely associated with complement decay-accelerating factor (DAF), which is present on intimal fibroblasts and extracellular matrix. Fc gammaRIII expression was minimal in normal forearm dermis, but widespread on CD45+ cells in skin exposed to mechanical stress. In skin containing rheumatoid nodules, Fc-gammaRIII was preferentially expressed on palisading macrophages. These observations indicate that expression of Fc gammaRIII on macrophages may be involved in the susceptibility of connective tissues to immune complex-induced damage in RA. Colocalization of Fc gammaRIII and DAF in synovium may indicate an unrecognized functional interrelationship.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9182883      PMCID: PMC1904688          DOI: 10.1046/j.1365-2249.1997.3941286.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  7 in total

1.  Expansion of a unique macrophage subset in rheumatoid arthritis synovial lining layer.

Authors:  M Tanaka; T Nagai; Y Tsuneyoshi; N Sunahara; T Matsuda; T Nakamura; S Tsuyama; K Hasui; O FitzGerald; T Matsuyama
Journal:  Clin Exp Immunol       Date:  2008-08-22       Impact factor: 4.330

2.  Tumour necrosis factor alpha independent disease mechanisms in rheumatoid arthritis: a histopathological study on the effect of infliximab on rheumatoid nodules.

Authors:  D Baeten; F De Keyser; E M Veys; Y Theate; F A Houssiau; P Durez
Journal:  Ann Rheum Dis       Date:  2004-05       Impact factor: 19.103

3.  Differential distribution of Fc gamma RIIIa in normal human tissues and co-localization with DAF and fibrillin-1: implications for immunological microenvironments.

Authors:  A Bhatia; S Blades; G Cambridge; J C Edwards
Journal:  Immunology       Date:  1998-05       Impact factor: 7.397

4.  Skewed balance in basal expression and regulation of activating v inhibitory Fcgamma receptors in macrophages of collagen induced arthritis sensitive mice.

Authors:  A B Blom; P L E M van Lent; A E M Holthuysen; C Jacobs; W B van den Berg
Journal:  Ann Rheum Dis       Date:  2003-05       Impact factor: 19.103

5.  Fc gamma R expression on macrophages is related to severity and chronicity of synovial inflammation and cartilage destruction during experimental immune-complex-mediated arthritis (ICA).

Authors:  A B Blom; P L van Lent ; H van Vuuren ; A E Holthuysen; C Jacobs; L B van de Putte ; J G van de Winkel ; W B van den Berg
Journal:  Arthritis Res       Date:  2000-08-31

6.  Rituximab and its potential for the treatment of rheumatoid arthritis.

Authors:  Adam Bryant; John Moore
Journal:  Ther Clin Risk Manag       Date:  2006-06       Impact factor: 2.423

7.  High synovial expression of the inhibitory FcgammaRIIb in rheumatoid arthritis.

Authors:  Sofia E Magnusson; Marianne Engström; Uwe Jacob; Ann-Kristin Ulfgren; Sandra Kleinau
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.